Recent data indicate that daratumumab can further decrease minimal residual disease burden when added to lenalidomide- and bortezomib-containing regimens in patients with relapsed/refractory multiple myeloma. Read More ›

Researchers conducted a systematic literature review and subsequent meta-analysis of progression-free survival outcomes to compare 16 different treatment regimens for relapsed/refractory multiple myeloma. Read More ›

An early access study confirms the safety and preservation of health-related quality of life of daratumumab in multiple myeloma. Read More ›

Combinations of targeted agents that include daratumumab offer synergy to alter the tumor microenvironment to promote the efficacy of these combinations in the treatment of multiple myeloma. Read More ›

PREAMBLE is an ongoing multinational observational study being conducted to evaluate real-world outcomes in patients with multiple myeloma. Here, researchers present preliminary efficacy analyses in patients with 1 line of prior therapy. Read More ›

A leading cancer clinic has developed an innovative response-adapted treatment protocol for newly diagnosed patients with multiple myeloma. Read More ›

Preliminary data suggest that subcutaneous delivery of daratumumab in patients with relapsed/refractory multiple myeloma is well-tolerated and yields similar response rates to intravenous administration of the drug. Read More ›

Daratumumab in combination with lenalidomide plus dexamethasone specifically induces robust increases in T-cell clonality. The finding provides support for an immune modulatory mechanism of daratumumab. Read More ›

Outcomes of patients with relapsed/refractory multiple myeloma are poor, but are improving as treatment options expand. Read More ›